Erratum To: PI3K/Akt/mTOR Signaling in Medullary Thyroid Cancer: A Promising Molecular Target for Cancer Therapy

Endocrine
doi 10.1007/s12020-016-1000-z
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

Acetylshikonin Inhibits Colorectal Cancer Growth via PI3K/Akt/mTOR Signaling Pathway

Chinese Medicine
2018English

Novel Expression Patterns of PI3K/Akt/mTOR Signaling Pathway Components in Colorectal Cancer

Journal of the American College of Surgeons
Surgery
2010English

CSNK2A1 Promotes Gastric Cancer Invasion Through the PI3K-Akt-mTOR Signaling Pathway

Cancer Management and Research
Oncology
2019English

Targeted Therapy for Advanced Prostate Cancer: Inhibition of the PI3K/Akt/mTOR Pathway

Current Cancer Drug Targets
Cancer ResearchDrug DiscoveryOncologyPharmacology
2009English

Targeting the PI3K/AKT/mTOR Pathway in Prostate Cancer Development and Progression: Insight to Therapy

Clinical Cancer Drugs
Cancer ResearchToxicologyOncologyPharmaceuticsPharmacology
2016English

Inhibition of Esophageal Cancer Growth Through the Suppression of PI3K/AKT/mTOR Signaling Pathway

OncoTargets and Therapy
OncologyPharmacology
2019English

NRSN2 Promotes Breast Cancer Metastasis by Activating PI3K/AKT/mTOR and NF‑κB Signaling Pathways

Oncology Letters
Cancer ResearchOncology
2019English

PSMA Redirects MAPK to PI3K-AKT Signaling to Promote Prostate Cancer Progression

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy